Drug Type Synthetic peptide |
Synonyms- |
Target |
Mechanism PIK3R3 inhibitors(phosphoinositide-3-kinase regulatory subunit 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurotrophic keratitis | Phase 2 | CN | 08 Aug 2024 | |
Xerophthalmia | Phase 2 | CN | 12 Sep 2023 | |
Rhinitis, Allergic, Perennial | Phase 2 | CN | 19 Sep 2022 | |
Conjunctivitis, Allergic | Phase 1 | CN | 25 Aug 2021 | |
Ocular inflammation | IND Approval | CN | 18 Mar 2024 | |
Vernal Keratoconjunctivitis | IND Approval | CN | 16 Dec 2022 | |
Acute irritant rhinitis | Preclinical | CN | 07 Dec 2019 | |
Chronic rhinitis | Preclinical | CN | 07 Dec 2019 | |
Sinusitis | Preclinical | CN | 07 Dec 2019 | |
Rhinitis, Allergic | Discovery | CN | 26 Jul 2021 |